Sentry Bioconvertible Inferior Vena Cava Filter: Study of Stages of Incorporation in an Experimental Ovine Model.

IF 2.5 Q2 PERIPHERAL VASCULAR DISEASE International Journal of Vascular Medicine Pub Date : 2018-07-19 eCollection Date: 2018-01-01 DOI:10.1155/2018/6981505
Peter A Gaines, Frank D Kolodgie, Gordon Crowley, Steven Horan, Megan MacDonagh, Emily McLucas, David Rosenthal, Ashley Strong, Michael Sweet, Deepal K Panchal
{"title":"Sentry Bioconvertible Inferior Vena Cava Filter: Study of Stages of Incorporation in an Experimental Ovine Model.","authors":"Peter A Gaines,&nbsp;Frank D Kolodgie,&nbsp;Gordon Crowley,&nbsp;Steven Horan,&nbsp;Megan MacDonagh,&nbsp;Emily McLucas,&nbsp;David Rosenthal,&nbsp;Ashley Strong,&nbsp;Michael Sweet,&nbsp;Deepal K Panchal","doi":"10.1155/2018/6981505","DOIUrl":null,"url":null,"abstract":"<p><p>The Sentry inferior vena cava (IVC) filter is designed to provide temporary protection from pulmonary embolism (PE) and then bioconvert to become incorporated in the vessel wall, leaving a patent IVC lumen. <i>Objective.</i> To evaluate the performance and stages of incorporation of the Sentry IVC filter in an ovine model. <i>Methods.</i> Twenty-four bioconvertible devices and 1 control retrievable filter were implanted in the infrarenal IVC of 25 sheep, with extensive daily monitoring and intensive imaging. Vessels and devices were analyzed at early (≤98 days, <i>n</i> = 10) and late (180 ± 30 days, <i>n</i> = 14 study devices, 1 control) termination and necropsy time-points. <i>Results.</i> Deployment success was 100% with all devices confirmed in filtering configuration, there were no filter-related complications, and bioconversion was 100% at termination with vessels widely patent. By 98 days for all early-incorporation analysis animals, the stabilizing cylindrical part of the Sentry frame was incorporated in the vessel wall, and the filter arms were retracted. By 180 days for all late-incorporation analysis animals, the filter arms as well as frames were stably incorporated. <i>Conclusions.</i> Through 180 days, there were no filter-related complications, and the study devices were all bioconverted and stably incorporated, leaving all IVCs patent.</p>","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2018-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/6981505","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Vascular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2018/6981505","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 5

Abstract

The Sentry inferior vena cava (IVC) filter is designed to provide temporary protection from pulmonary embolism (PE) and then bioconvert to become incorporated in the vessel wall, leaving a patent IVC lumen. Objective. To evaluate the performance and stages of incorporation of the Sentry IVC filter in an ovine model. Methods. Twenty-four bioconvertible devices and 1 control retrievable filter were implanted in the infrarenal IVC of 25 sheep, with extensive daily monitoring and intensive imaging. Vessels and devices were analyzed at early (≤98 days, n = 10) and late (180 ± 30 days, n = 14 study devices, 1 control) termination and necropsy time-points. Results. Deployment success was 100% with all devices confirmed in filtering configuration, there were no filter-related complications, and bioconversion was 100% at termination with vessels widely patent. By 98 days for all early-incorporation analysis animals, the stabilizing cylindrical part of the Sentry frame was incorporated in the vessel wall, and the filter arms were retracted. By 180 days for all late-incorporation analysis animals, the filter arms as well as frames were stably incorporated. Conclusions. Through 180 days, there were no filter-related complications, and the study devices were all bioconverted and stably incorporated, leaving all IVCs patent.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
哨兵生物可转换下腔静脉过滤器:在实验羊模型中掺入阶段的研究。
Sentry下腔静脉(IVC)过滤器旨在提供暂时的保护,防止肺栓塞(PE),然后生物转化为与血管壁结合,留下一个专利的下腔静脉管腔。目标。评估Sentry IVC过滤器在羊模型中的性能和阶段。方法。将24个生物转换装置和1个对照可回收过滤器植入25只羊的肾下IVC,进行广泛的日常监测和强化成像。在早期(≤98天,n = 10)和晚期(180±30天,n = 14个研究装置,1个对照)终止和尸检时间点对血管和器械进行分析。结果。所有设备的过滤配置都得到了确认,部署成功率为100%,没有出现与过滤器相关的并发症,并且在血管广泛专利的情况下,生物转化率为100%。到第98天,所有早期掺入分析动物的Sentry框架的稳定圆柱形部分被纳入血管壁,过滤臂被收回。到180天,所有晚入组分析动物的滤光臂和镜架都稳定入组。结论。通过180天,没有过滤器相关的并发症,研究设备都是生物转化和稳定纳入,留下所有IVCs专利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Vascular Medicine
International Journal of Vascular Medicine PERIPHERAL VASCULAR DISEASE-
CiteScore
3.50
自引率
0.00%
发文量
7
审稿时长
16 weeks
期刊最新文献
Analyzing Cardiovascular Disease Research in the Arab Region: A Bibliometric Review From 2012 to 2022. Long-Term Clinical and Imaging Findings in Patients with Lower Extremity Varicose Veins Treated with Endovenous Laser Treatment: A Follow-Up Study of up to 12 Years. Angiopoietin-2 Is Associated with Aortic Stiffness in Diabetes Patients in Ghana: A Case-Control Study. Aerobic Exercise versus Electronic Cigarette in Vascular Aging Process: First Histological Insight. Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1